In particular, concerns regarding anti-TNF-α therapy’s safety profile, including its potential association with an increased risk of lymphoma, partly stem from the fact that patients with RA already exhibit a moderately higher risk of lymphoma than the general population due to factors such as chronic inflammation, immune dysregulation, and genetic predispositions. This evidence concerns the gene TNF and rheumatoid arthritis.